Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene

Programa de Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] (Impact Factor: 1.01). 11/2009; 42(12):1218-24. DOI: 10.1590/S0100-879X2009007500011
Source: PubMed


Malignant hyperthermia (MH) is a pharmacogenetic disease triggered in susceptible individuals by the administration of volatile halogenated anesthetics and/or succinylcholine, leading to the development of a hypermetabolic crisis, which is caused by abnormal release of Ca2+ from the sarcoplasmic reticulum, through the Ca2+ release channel ryanodine receptor 1 (RyR1). Mutations in the RYR1 gene are associated with MH in the majority of susceptible families. Genetic screening of a 5-generation Brazilian family with a history of MH-related deaths and a previous MH diagnosis by the caffeine halothane contracture test (CHCT) in some individuals was performed using restriction and sequencing analysis. A novel missense mutation, Gly4935Ser, was found in an important functional and conserved locus of this gene, the transmembrane region of RyR1. In this family, 2 MH-susceptible individuals previously diagnosed with CHCT carry this novel mutation and another 24 not previously diagnosed members also carry it. However, this same mutation was not found in another MH-susceptible individual whose CHCT was positive to the test with caffeine but not to the test with halothane. None of the 5 MH normal individuals of the family, previously diagnosed by CHCT, carry this mutation, nor do 100 controls from control Brazilian and USA populations. The Gly4932Ser variant is a candidate mutation for MH, based on its co-segregation with disease phenotype, absence among controls and its location within the protein.

Download full-text


Available from: Gisele Zapata-Sudo, Aug 18, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant hyperthermia (MH) is an autosomal dominant pharmacogenetic disorder that is manifested on exposure of susceptible individuals to halogenated anesthetics or succinylcholine. Since MH is associated primarily with mutations in the ryanodine receptor type 1 (RYR1) gene, the purpose of this study was to determine the distribution and frequency of MH causative RyR1 mutations in the Canadian MH susceptible (MHS) population. In this study, we screened a representative cohort of 36 unrelated Canadian MHS individuals for RYR1 mutations by sequencing complete RYR1 transcripts and selected regions of CACNA1S transcripts. We then analyzed the correlation between caffeine-halothane contracture test (CHCT) results and RYR1 genotypes within MH families. Eighty-six percent of patients had at least one RyR1 mutation (31 out of 36), five of which were unrelated individuals who were double-variant carriers. Fifteen of the 27 mutations identified in RYR1 were novel. Eight novel mutations, involving highly conserved amino acid residues, were predicted to be causal. Two of the mutations co-segregated with the MHS phenotype within two large independent families (a total of 79 individuals). Fourteen percent of MHS individuals (five out of 36) carried neither RYR1 nor known CACNA1S mutations. The distribution and frequency of MH causative RyR1 mutations in the Canadian MHS population are close to those of European MHS populations. Novel mutations described in this study will contribute to the worldwide pool of MH-associated mutations in the RYR1 gene, ultimately increasing the value of MH genetic diagnostic testing.
    Canadian Anaesthetists? Society Journal 03/2011; 58(6):504-13. DOI:10.1007/s12630-011-9494-6 · 2.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Adverse drug reactions (ADRs) are common. Causation is complex and depends on clinical, environmental, and genetic factors. There are genetic predisposing factors in pharmacokinetic and pharmacodynamic pathways. Most studies have focused on candidate gene approaches, but unbiased genome-wide association studies are also being used. Implementation of pharmacogenetic tests to prevent ADRs depends on a number of factors, including the strength of the association, the test characteristics, the practicality of performing the test, and its cost-effectiveness. The demonstration of both clinical validity and clinical usefulness is rare for most pharmacogenetic tests, but it is important that investigators start adopting approaches that will provide such evidence, because without this it is unlikely that effective pharmacogenetic tests will be acceptable to clinicians, patients, regulators, and health-care providers.
    Preventive and Predictive Genetics: Towards Personalised Medicine, 1 edited by Godfey Grech, Iris Grossman, 01/2015: chapter 6: pages 109-156; Springer International Publishing., ISBN: 978-3-319-15343-8 (Print) 978-3-319-15344-5 (Online)